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Abstract
Background: 6-Aminophenanthridine (6AP) and Guanabenz (GA, a drug currently in use for the treatment of hypertension)
were isolated as antiprion drugs using a yeast-based assay. These structurally unrelated molecules are also active against
mammalian prion in several cell-based assays and in vivo in a mouse model for prion-based diseases.
Methodology/Principal Findings: Here we report the identification of cellular targets of these drugs. Using affinity
chromatography matrices for both drugs, we demonstrate an RNA-dependent interaction of 6AP and GA with the ribosome.
These specific interactions have no effect on the peptidyl transferase activity of the ribosome or on global translation. In
contrast, 6AP and GA specifically inhibit the ribosomal RNA-mediated protein folding activity of the ribosome.
Conclusion/Significance: 6AP and GA are therefore the first compounds to selectively inhibit the protein folding activity of
the ribosome. They thus constitute precious tools to study the yet largely unexplored biological role of this protein folding
activity.
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Introduction
Prion-based diseases are fatal neurodegenerative disorders for
which no efficient treatment is currently available [1]. These
diseases are caused by proteinaceous infectious particles termed
prions. According to the ‘‘protein only’’ hypothesis, prions are
composed solely of an abnormal form of the PrP protein, a GPI
anchored protein normally present at the surface of numerous cell
types including neurons. PrP exists in two forms, a ‘‘normal’’ form
(PrP
C) and a pathological, misfolded and protease resistant form
(PrP
Sc). During the course of disease, PrP
Sc accumulates and is
capable of converting the normal PrP
C form to this altered
conformation [2]. PrP
Sc presents an increase in b-sheet structure
[3] and forms aggregates [4]. Prion-based diseases are thus related
to other protein misfolding disorders such as Alzheimer, Parkinson
or Huntington diseases, which are all characterized by the
accumulation of intracellular or extracellular b-sheet rich protein
aggregates.
Prions also exist in fungi. In 1994, Reed B. Wickner provided
genetic evidence that a long known genetic element of the budding
yeast Saccharomyces cerevisiae with unusual cytoplasmic inheritance
was in fact a prion [5]. Other prions were then discovered in yeast
and in filamentous fungi (reviewed in [6]) and several simple
reporter systems have been developed to investigate their behavior
[7,8]. These model systems provided direct support for the
‘‘protein-only’’ hypothesis and indicated that fungal prions
correspond to self-propagating amyloid or amyloid-like assemblies
[9–13].
Since prion replication corresponds to the propagation of a
misfolded state, the chaperone network plays a central role in
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2174prion appearance and maintenance [14]. The chaperone network
controls proper folding of newly synthesized proteins, assists
assembly of macromolecular complexes and promotes clearance of
protein aggregates. The protein chaperone activity is carried out
by soluble chaperones and ribosome-associated chaperones. In
addition, the ribosome itself was found to possess an intrinsic
protein folding activity [15–26]. In yeast, prion propagation was
demonstrated to be critically dependent on the chaperone
machinery, and in particular on Hsp104p chaperone [27]. In
addition it is also modulated by different members of the Hsp70p
and Hsp40p family and additional co-chaperones [14].
Several approaches towards the development of prion disease
therapies are currently being explored. These include identifica-
tion of pharmacological drugs, immunotherapeutics and PrP
C
knockdown by RNA interference [1]. Recently a peptide aptamers
approach has been developed [28]. Therapeutics can target PrP
C,
PrP
Sc or the conversion process. Among the experimental systems
used are animal models, cell culture and cell-free conversion
assays. Relatively few studies have used systematic screening
approaches of large chemical libraries. Recently we have
developed a simple, cost-effective, safe and rapid yeast-based
method to screen large chemical libraries for antiprion drugs
[29,30]. In a first screen, molecules are isolated on the basis of
their in vivo activity against the [PSI
+] yeast prion. The active
compounds are then further tested against [URE3], a second yeast
prion which is unrelated to [PSI
+]. Both screens use a colorimetric
detection system in which prion-containing yeast cells form white
colonies whereas loss of prion leads to formation of red colonies.
Remarkably, a vast majority of molecules identified using this
yeast-based assay were also active against mammalian prion ex vivo
in various mammalian cell-based assays ([29–31] and D. V. and
M. B. unpublished results) and in vivo for the few that were tested
(Tribouillard-Tanvier et al. in press). This finding not only validates
our yeast-based assay for high-throughput screening of antiprion
molecules, but also establishes yeast as a relevant model system to
study mammalian prion-based diseases. Furthermore, some of the
antiprion drugs isolated using mammalian cell-based assays, like
Quinacrine (QC) or Chlorpromazine (CPZ), were found to be
active in the yeast-based assay [29]. Taken together, these results
strongly suggest that at least some prion-controlling mechanisms
are conserved from yeast to mammals.
For this reason we sought to identify intracellular targets of two
of the most active compounds identified using the yeast-based
assay: 6-aminophenanthridine (6AP) and Guanabenz (GA, a drug
already on the market for the treatment of hypertension
(Tribouillard et al., in press)). We have designed affinity
chromatography matrices to identify the drugs interactants. We
show that the two unrelated antiprion drugs 6AP and GA interact
with ribosome in an RNA-dependent manner and specifically
inhibit ribosomal protein folding activity, which is carried by the
large ribosomal RNA (23S rRNA in E. coli, 25S rRNA in S.
cerevisiae and 28S rRNA in mammals) of the large subunit. 6AP and
GA do however not affect protein synthesis neither in vivo nor in
vitro.
Results
6AP and GA and their inactive derivatives lacking
antiprion activity
6AP (6-aminophenanthridine, molecular structure depicted in
Figure 1a) is a potent derivative of phenanthridine, a compound
originally isolated from our laboratory chemical library as active
against prions using the yeast-based assay described above [29,30].
6AP was found to be also active against mammalian prion in three
mammalian cell-based assays ([29,31] and Figure 1a, upper gel),
namely the Rov system (rabbit kidney epithelial cells stably
infected by the 127S sheep prion strain [32]), the N2a system
(murine neuroblastoma cells stably infected by the RML murine
prion strain [33,34]) and the MovS6 system (immortalized
neuroglial cells from ovine transgenic mice chronically infected
by the 127S sheep prion strain [35]). In all these assays, PrP
Sc was
detected on the basis of its proteinase K resistance. Guanabenz
(GA, molecular structure depicted in Figure 1b) is an orally active
central a2-adrenoceptor agonist already on the market for the
treatment of hypertension [36]. Very recently, we identified this
drug as active against both [PSI
+] and [URE3] yeast prions
(Tribouillard et al., in press and Figure 1b) as well as against
mammalian prion, not only ex vivo in the MovS6-based assay
described above but also in vivo in a mouse model previously
described (tg338 mice infected with the 127S strain [37]).
In order to generate relevant controls, we reasoned that it could
be of interest to design close derivatives of 6AP and GA lacking
antiprion activity. During the course of structure-activity relation-
ship (SAR) studies on the 6AP chemical family, numerous
derivatives were synthesized. 6APi was obtained by introducing
a 2-(butan-1-ol) group (depicted in blue in Figure 1a) on the 6-
amino position of 6AP. 6APi is totally inactive against both [PSI
+]
and [URE3] yeast prions and also against mammalian prion in the
MovS6-based assays (Figure 1a lower panels). 6APi thus
represents a proper negative control for experiments involving
6AP: despite its structural similarity with 6AP, it is totally inactive
against both yeast and mammalian prions.
The SAR studies performed on the GA family suggested GAi is
the most appropriate control molecule. GAi (Figure 1b, bottom
structure) differs from GA by a single replacement of one of the
two chlorine by a fluorine (also a halogen, highlighted in blue).
This new molecule is totally inactive against yeast and mammalian
prions (Tribouillard et al., in press and Figure 1b lower panels).
Design of 6AP and GA affinity matrices
In order to identify the cellular targets of 6AP and GA, we
synthesized 6AP- and GA-linked affinity chromatography matrices
to purify intracellular macromolecules able to physically interact
with these drugs [38]. To avoid possible steric hindrance between
target(s) and the matrix, we introduced a spacer between 6AP or
GA and the sepharose beads. An aminocaproylaminopentyloxy
linker was chosen because of its optimal length (F. G. and H. G., in
preparation). In addition, its internal peptidic bond lowers its
hydrophobicity, therefore reducing potential auto-aggregation or
unspecific hydrophobic interactions with macromolecules from
cell lysates. Furthermore, the amide function increases the rigidity
of the linker. The position where this aminocaproylaminopenty-
loxy extension can be introduced while maintaining the antiprion
activity of 6AP or GA was determined by testing the antiprion
activity of their derivatives with the linker in various positions.
Concerning 6AP, a previous SAR study has indeed shown that all
but positions 1, 2 and 3 were crucial for its antiprion activity (F.G.,
N.D., M.B. and H.G., in preparation). Introduction of the
aminocaproylaminopentyloxy linker in position 3 led to a
reasonably active chemical derivative of 6AP, while the two other
substitutions led to completely inactive compounds (Figure 1c
upper panel). Similarly, introduction of the linker in position 4 of
GA did not strongly affect its activity (Figure 1c lower panel). The
branched 6AP and GA molecules were then bound to sepharose
beads via the amino group of the linker to yield the affinity
chromatography matrices depicted in Figure 1d. As control,
sepharose beads quenched with ethanolamine were prepared.
The Target of Antiprion Drugs
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2174Figure 1. Absence of antiprion activity of 6APi and GAi, two close derivatives of antiprion drugs 6AP and GA and synthesis of
affinity matrices for both drugs. a. Left panels: the molecular structure of 6AP and 6APi are depicted. Simple introduction of a 2-(butan-1-ol)
group (represented in blue) on the amino group in position 6 is sufficient to abolish the antiprion activity of 6AP. Middle panels: aliquots of an
overnight culture of a [PSI
+] strain (left panel, STRg6) and of a [URE3] strain (right panel, SB34), both growing as white colonies (because they contain
prions: see Materials and Methods), were spread on YPD medium supplemented with 200 mM GuHCl. Small filters (similar to the ones used for
antibiograms) were placed on the agar surface. 10 ml of a 10 mM solution in DMSO of 6AP (top) and 6APi (bottom) were spotted on the filters. The
Petri plates were then incubated three days at 25uC. Red halos were observed around the filters where 6AP was loaded, but not around those where
6APi was spotted indicating that, in contrast to 6AP, 6APi is inactive against yeast prions. Right panels: Scrapie-infected MovS6 cells were treated for
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experiments to identify cellular targets of 6AP or GA.
6AP and GA do not interact directly with prion proteins
Crude extracts of budding yeast, porcine brain or MovS6
(murine neuroglial) cells were prepared and incubated for
30 minutes with 6AP beads, GA beads or control beads. As
additional controls, competitions with an excess of free 6AP or
6APi, respectively, or free GA or GAi, respectively, were
performed, the rationale being that targets of the antiprion activity
of 6AP or GA should be specifically competed away from the
beads by 6AP or GA but not by 6APi or GAi, respectively. After
extensive washing, bound proteins were eluted with SDS-PAGE
sample buffer.
In principle, two mechanisms of action for antiprion drugs can
be envisioned: either a cis mechanism, targeting prion protein/
aggregates directly, or a trans mechanism, interfering with the
activity of cellular factor(s) required for prion propagation. In the
latter mechanism, antiprion drugs are not expected to interact
directly with the prion proteins whereas the former mechanism
implies direct interaction of the compound with the prion proteins
either in their normal or prion form. Therefore proteins bound to
6AP beads were analyzed by SDS-PAGE followed by Western
blotting using antibodies directed against Sup35p (the protein
corresponding to [PSI
+] prion), Ure2p (the protein corresponding
to [URE3] prion) or PrP. Although these three proteins were
clearly detectable in crude cell extracts, they could not be detected
among the components eluted from the 6AP beads after
chromatography (Figure 2a), suggesting that there is no direct
interaction between 6AP and these prion-forming proteins. This
observation is consistent with the fact that 6AP is active against
three prions ([PSI
+], [URE3] and PrP
Sc) which do not share any
significant sequence similarity. Moreover, no effect of 6AP or GA
was observed on in vitro PrP
C to PrP
Sc conversion using a highly
sensitive Protein Misfolding Cyclic Amplification (PMCA) method
[39] (Figure 2b and data not shown), further strengthening the
view that there is no direct interaction between prion proteins and
6AP or GA. Similarly, we found no significant effect of either 6AP
and 6APi or GA and GAi on prion amyloid formation rate of
purified recombinant Ure2p protein (Figure S1a and c). The
same result was obtained using a second amyloid-forming prion
protein, namely the prion forming domain (PFD) of the HET-s
prion protein of Podospora anserina (Figure S1b), which is
consistent with previous observations using an in vitro filter trap
assay [40]. Taken together, these results suggest that 6AP and GA
act in trans on cellular factors rather than in cis directly on the prion
proteins.
6AP and GA show specific interactions with ribosomal
components
Proteins bound to 6AP or GA beads were analyzed by SDS-
PAGE followed by Coomassie blue (not shown) and silver staining
(Figure 2c). Specific protein bands (absent from control beads,
present on 6AP or GA beads and respectively competed away by
free 6AP but not by free 6APi or by free GA but not by free GAi)
were excised from the gel for identification by mass spectrometry.
Most of the identified bands corresponded to ribosomal proteins
from both the large and the small ribosomal subunits (Table S1
and data not shown), suggesting that the ribosome or at least
ribosome components could be specific targets of 6AP and GA. In
the case of 6AP, some members of the Hsp70 family were also
identified but only when using yeast extracts. These bound
proteins (bands marked with an ‘‘i’’) correspond to Ssa2p, Ssb1p
and Ssb2p. Since these proteins were found to interact only with
6AP and not GA and only in yeast extracts and because they are
described as ribosome-interacting proteins, interaction with these
Hsp70 family members was not analyzed further.
We conclude that 6AP and GA, two chemically unrelated
antiprion drugs isolated from two independent chemical libraries,
appear to share the same cellular targets, namely components of
the ribosome.
6AP and GA share common or overlapping binding sites
on ribosomal components
We next tested whether 6AP and GA share the same interaction
site(s) on ribosomal constituents by determining the ability of each
compound to compete for the binding of ribosomal proteins to the
other compound. As shown on lanes 5 and 6 of the left gel in
Figure 2d, GA (but not GAi) is able to compete for the binding of
ribosomal proteins to 6AP beads. Conversely, 6AP (but not 6APi)
is able to compete for the binding of ribosomal proteins to GA
beads (lanes 5 and 6, right panel). Taken together, these results
suggest that 6AP and GA share common (or at least partially
overlapping) binding site(s) on ribosomal components.
6AP and GA interaction with ribosomal components is
RNA-dependent
Next we wondered whether the interaction of 6AP and GA with
ribosomal proteins was dependent on RNA. We observed that an
RNase A treatment of yeast crude extracts before affinity
chromatography purification completely abolished the binding of
the ribosomal proteins (and Hsp70s) to both 6AP (Figure 3a, lane
3) and GA beads (Figure 3b, lane 3). The same results were
obtained using extracts from porcine brain or MovS6 cells (data
not shown). We conclude that binding of ribosomal proteins to
6AP and GA is RNA-dependent. These results readily explain why
a large number of distinct ribosomal proteins were retained by the
affinity matrices.
6AP and GA have no effect on protein synthesis in vivo
and in vitro
Because the main function of the ribosome is protein synthesis,
the effect of 6AP and GA on translation was assessed both in vivo
and in vitro. Exponentially growing [PSI
+] yeast cells were treated
with various compounds as indicated, at a final concentration of
100 mM (a concentration known to have an antiprion effect in
six days with DMSO (2)o r2 0mM( +) 6AP (upper gel) or 6APi (lower gel) and then lysed. Cell lysates were then subjected to proteinase K digestion
(only PrP
Sc is resistant to proteinase K) followed by Western blot analysis using an anti-PrP antibody. Note that, as observed with yeast prions, only
6AP was active against PrP
Sc. b. Same experiments performed with GA and its inactive derivative GAi. Note that only GA is active against both [PSI+]
and [URE3] yeast prions and mammalian prion in the MovS6 cell-based assay. c. A linker (aminocaproylaminopentyloxy) was attached in position 1, 2
or 3 of 6AP (top 3 structures) or in position 4 of GA (lower structure) as depicted in the molecular structures shown. The corresponding 6AP
derivatives were tested for their activity against the [PSI
+] prion (using the same strain and method as in Figure 1a and b). Note that only the 6AP
derivative carrying the linker in position 3 (top panel) retains a significant antiprion activity. In the case of GA, the derivative carrying the linker in
position 4 is still active. d. Molecular structures of 6AP (top) or GA (bottom) beads with the linker in position 3 on 6AP and 4 on GA, covalently linked
to sepharose beads are shown.
doi:10.1371/journal.pone.0002174.g001
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PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2174Figure 2. 6AP and GA do not interact with prion proteins but show specific interactions with ribosomal components and compete
with each other for interaction with ribosomal components. a. Extracts from yeast (left panel), porcine brain (middle panel) and murine
MovS6 cells (right panel) were incubated with 6AP beads. The beads were then washed extensively and the bound proteins analyzed by SDS-PAGE
followed by Western blotting analysis using antibodies directed against Sup35p, Ure2p or PrP as indicated. 1: crude extracts, 2: control beads without
6AP, 3: chromatography using 6AP beads. Note that none of the three prion proteins binds to 6AP beads. b. Protein Misfolding Cyclic Amplification
(PMCA) reactions performed in the presence of various compounds and then subjected to proteinase K digestion followed by Western blot analysis
using an anti-PrP antibody. All samples contain a mixture of normal and scrapie brain homogenates in addition to the tested compounds at various
concentrations as indicated in the right panel. Note that both 6AP and 6APi are unable to inhibit in vitro conversion of PrP
C to PrP
Sc. c. Extracts from
yeast (left panel), porcine brain (middle panel) and murine MovS6 cells (right panel) were incubated with 6AP beads. The beads were then washed
extensively and the bound proteins analyzed by SDS-PAGE. Lane 1: control beads without 6AP, lane 2: chromatography using 6AP beads, lane 3:
The Target of Antiprion Drugs
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Radiolabelled [
35S] methionine was then added for 10 minutes
and cells were harvested. Extracts were prepared and analyzed by
SDS-PAGE (Figure 4a) or 2D-gel electrophoresis (Figure 4b)
followed by autoradiography. None of the tested compounds
exhibited a significant effect (inhibition or activation) on global
protein synthesis. In addition, 6AP and GA had no significant
specific effect on Sup35p, PrP or Ure2p protein level ([29] and
data not shown). In sharp contrast, cycloheximide (CHX), a
known inhibitor of global translation [41], completely inhibited
protein synthesis at this concentration. The effect of 6AP and GA
was also tested in an in vitro translation system based on rabbit
reticulocyte lysate. The translation efficiency of a control mRNA
encoding for the EF1A translation factor was evaluated in the
presence of 200 mM of the indicated compounds (Figure 4c).
Again, only CHX significantly inhibited EF1A mRNA translation.
Therefore, at concentrations at which they exhibit antiprion
activity, neither 6AP nor GA affects protein synthesis in these in
vivo and in vitro systems.
6AP and GA inhibit the rRNA-mediated protein folding
activity of the ribosome
In addition to its role in protein synthesis, the ribosome also
assists protein folding. This ability has been demonstrated in vitro
using bacterial as well as eukaryotic ribosomes and a variety of
different proteins as substrates [15–17,19–21,23] and is supported
by in vivo data in E. coli [18]. In all cases studied so far, this protein
folding activity of the ribosome was shown to be mainly due to the
domain V of the large rRNA (23S rRNA in E. coli) of its large
subunit (50S in E. coli). This large rRNA, and particularly its
domain V, is also involved in peptidyl transferase activity [42].
Since binding of 6AP and GA to the ribosome is RNA-dependent
and exhibits no inhibitory effect on protein synthesis, we wondered
if these drugs might modulate the protein folding activity of the
ribosome. Human Carbonic Anhydrase (hCA) was used as a
substrate for in vitro assisted folding experiments (Figure 5). The
hCA protein was denaturated in the presence of guanidium
hydrochloride and EDTA. For refolding experiments, hCA was
diluted 100 times in native buffer either alone (to determine self-
folding efficiency) or in the presence of highly active preparations
of E. coli 70S ribosome, or the large subunit (50S), or rRNA
purified from the 50S subunit (23S rRNA and 5S rRNA), or an in
vitro transcribed 660 nucleotides long domain V from B. subtilis (see
experimental scheme in Figure 5a and results in Figure 5b, left
panel). The correct refolding of hCA was assessed by following the
reappearance of its enzymatic activity. Self-folding restored about
20% of hCA activity. E. coli ribosomes or the 50S subunit alone
restored about 70% of hCA activity, the 23S rRNA about 45%
and the in vitro transcribed domain V about 35%. The extent of the
assisted folding achieved by the different ribosomal folding
modulators strongly depends on the structural integrity of the
rRNA, which is probably better in 70S and 50S than in the
phenol-extracted 23S rRNA and worse in the in vitro transcribed
domain V. In control experiments, neither heparin (a control
folding modulator with a negatively-charged backbone like RNA)
nor tRNA (at concentration ranging from 2.33 mMt o7 0mM
which is several order of magnitude higher than the one at which
ribosome or ribosomal components are efficient) were able to assist
refolding of hCA, thus confirming that the protein folding activity
of the large rRNA of the large subunit of the ribosome is specific
and cannot be undertaken by other polyanions (Figure 5c, left
and middle panels). The same result was obtained using BSA (right
panel). 6AP and GA dramatically inhibited the ribosome-, 50S-,
23S- rRNA- and domain V-assisted folding to the level of self-
folding (about 20%). This inhibition was specific since neither
6APi nor GAi showed any effect when added at the same
concentration. Therefore, the potency of the four tested
compounds (6AP, 6APi, GA and GAi) to inhibit the assisted
folding activity of the ribosome parallels their activity as antiprion
drugs. The same results were obtained using preparation of S.
cerevisiae ribosome (Figure 5b, right panel) and other enzymes
(porcine Malate Deshydrogenase and bovine Carbonic Anhydrase,
data not shown) as substrates, suggesting that the ability of 6AP
and GA to inhibit the protein folding activity of the ribosome is a
general feature not restricted to bacterial systems.
We next determined whether the tested compounds could also
affect the peptidyl transferase activity of the ribosome under the
same experimental conditions (same preparation of E. coli
ribosomes, same drugs and ribosome concentrations). As shown
in Figure S2a, formation of the dipeptide (ML), a classical assay
Figure 3. 6AP and GA interaction with ribosomal components
is RNA-dependent. Crude yeast cell extracts were incubated with 6AP
beads (left) or GA beads (right). Lane 1: control beads without 6AP or
GA, lane 2: chromatography using 6AP or GA beads, lane 3: cellular
extracts were treated by RNase A at 100 mg/ml for 20 minutes at room
temperature before affinity chromatography experiments. The bound
proteins were analyzed by SDS-PAGE followed by silver staining. Note
that after treatment of cellular extracts by RNase A, ribosomal
constituents are unable to bind to 6AP or GA beads, indicating that
interaction between both compounds and the ribosomal constituents is
RNA-dependent.
doi:10.1371/journal.pone.0002174.g003
competition with free 6AP, lane 4: competition with free 6APi, the inactive derivative of 6AP (see Figure 1a). Gels were silver-stained and specific
bands were excised and analyzed by mass spectrometry. Note that for all the tested extracts, most of specific bands correspond to ribosomal proteins
(see also table S1). d. Crude yeast cell extracts were incubated with 6AP beads (left gel) or GA beads (right gel). Lane 1: control beads without 6AP or
GA, lane 2: chromatography using 6AP or GA beads, lanes 3 and 5: competition with free 6AP or GA, lanes 4 and 6: competition with free 6APi or GAi.
The bound proteins were analyzed by SDS-PAGE followed by silver-staining. Note that both 6AP and GA (but not 6APi and GAi) are able to compete
for the binding of ribosomal components to both 6AP and GA beads, suggesting that they share common binding site(s).
doi:10.1371/journal.pone.0002174.g002
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by any of the four compounds. The same result was obtained in
another experiment where the ability of ribosome to recycle was
assessed, thus giving a global view on translation efficiency (data
not shown).
An in vivo assay of ribosomal protein folding activity has only
been described in bacteria so far [18]. This assay is based on the
comparison of the b-Galactosidase (b-Gal) activity in E. coli cells
treated either by streptomycin or by chloramphenicol, both
antibiotics inhibiting translation but having different effects on
ribosomal protein folding activity in vitro. Streptomycin inhibits
translation by binding to the small subunit of the bacterial
ribosome and has thereby no effect on ribosomal folding activity in
vitro, while chloramphenicol binds to the domain V of the 23S
rRNA of the large subunit of the bacterial ribosome thus also
inhibiting ribosomal protein folding activity in vitro. When E. coli
cells are treated with either antibiotic, translation is totally
inhibited as determined by pulse-chase assays ([18] and Figure
S2b). In chloramphenicol-treated cells, the increase of b-Gal
activity as a function of time immediately stops, while in
streptomycin-treated cells, a significant (,30%) increase of total
b-Gal activity is observed. This difference was attributed to the
fact that streptomycin-treated cells retain the protein folding
activity of the ribosome and are thus able to properly fold the
newly synthesized b-Gal molecules, i.e. synthesized just before the
antibiotic totally inhibited translation ([18] and Figure 6b). The
ability of 6AP, 6APi, GA or GAi to inhibit this 30% increase in b-
Gal activity in streptomycin-treated E. coli cells was thus tested.
Both 6AP and GA were able to efficiently inhibit the increase in b-
Gal activity, whereas both 6APi and GAi were inactive (Figure 6b
and data not shown), suggesting that 6AP and GA inhibited the in
vivo protein folding activity of domain V. As controls, we checked
that none of the four drugs inhibits translation, as judged by pulse-
chase analysis (Figure S2b).
Taken together, these results demonstrate that 6AP and GA
specifically inhibit the protein folding activity of the ribosome both
in vitro and in vivo in E. coli without affecting its protein synthesis
function.
6AP and GA specifically interact with common positions
in domain V of the large rRNA of the large ribosomal
subunit
In order to test the ability of 6AP and GA to directly interact
with domain V of the large rRNA of the large subunit of the
ribosome, we performed chemical foot-printing experiments on
in vitro transcribed domain V of B. subtilis 23S rRNA as well as
on two other completely unrelated in vitro transcribed RNAs,
namely tRNA
Ser and RNAse P RNA. The results presented in
Figure 6a show that none of the antiprion drugs (6AP and GA)
nor their inactive analogues (6APi and GAi) were able to protect
any region of tRNA
Ser and RNAse P RNA (left and middle
panels). In contrast, foot-printing experiments on domain V of
23S rRNA showed specific and identical protection sites with
both 6AP and GA but not with their inactive derivatives (right
panel). These results clearly show a direct and specific binding of
both 6AP and GA to the domain V of the 23S rRNA. Here
again, the results obtained with the four compounds (6AP, 6APi,
GA and GAi) parallel their respective activities as antiprion
drugs.
Discussion
In this article we show that the ribosome is a common
intracellular target of 6AP and GA, two chemically unrelated
antiprion drugs active from yeast to mammals. Importantly, these
two drugs strongly and specifically inhibit the protein folding
activity of the ribosome without affecting its protein synthesis
activity. Ribosomal components were shown to interact specifically
and in an RNA-dependent manner with both 6AP and GA.
Control experiments using 6APi and GAi, two molecules
structurally very close to 6AP and GA, but totally devoid of
antiprion activity, highlight the specificity of 6AP and GA’s
Figure 4. 6AP and GA do not affect the translational activity of the ribosome both in vivo and in vitro.a .The effect of the indicated
compounds on general in vivo translation in living yeast cells was evaluated. Briefly, various drugs or DMSO (the compounds vehicle) alone were
added to yeast cells in exponential growth in YPD rich medium at a final concentration of 100 mM. After 10 minutes, radiolabelled [
35S] methionine
was added for 10 minutes. The cells were harvested to prepare cell extracts which were then analyzed by SDS-PAGE followed by autoradiography.
Note that, with the exception of cycloheximide (CHX, a known inhibitor of general translation), none of the tested compounds has a significant effect
on global protein synthesis. b. WT yeast cells were grown in the presence of DMSO (control left panel) or 100 mM 6AP (this concentration allows an
efficient cure of prion) and cell extracts were then analyzed by 2D-SDS-PAGE followed by autoradiography. Note that no significant difference was
observed between 6AP-treated cells and control cells. c. Effect of the indicated compounds on in vitro expression of EF1A using a commercial kit
(Ambion). Note that only cycloheximide (CHX) significantly inhibits synthesis of EF1A.
doi:10.1371/journal.pone.0002174.g004
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PLoS ONE | www.plosone.org 7 May 2008 | Volume 3 | Issue 5 | e2174Figure 5. 6AP and GA specifically inhibit the protein folding activity of the ribosome in vitro.a .Scheme depicting the principle of the in
vitro assay to evaluate the protein folding activity of the ribosome. Human Carbonic Anhydrase (hCA) was denaturated (using GuHCl and EDTA) and
then diluted into native buffer to allow refolding. Correct refolding was assessed by measuring the recovery of enzymatic activity as a function of
time. Spontaneously, about 20% of the enzyme is able to refold correctly (Self folding, upper part of the scheme). If either a preparation of ribosomes,
or the large subunit (50S), or the 23S rRNA, or the domain V of 23S rRNA, are added, the fraction of enzyme able to refold correctly increases up to
70%, due to the protein folding activity of the domain V of 23S rRNA of the large subunit of the ribosome (Assisted Folding -AF-, lower part of the
scheme). b. Effect of the various drugs (as indicated) on assisted folding of hCA by eukaryotic (yeast S. cerevisiae, right panel) or prokaryotic (E. coli left
panel) ribosomes (or indicated part of it). Concentration of each folding modulator is indicated. Note that only GA and 6AP, but not GAi and 6APi,
were able to inhibit the assisted folding down to the level of self folding. c. Effect of heparin (left panel), tRNA (central panel) or BSA (right panel) on
assisted folding of hCA. Note that none of these molecules is able to assist folding of hCA. Negative control is self folding and positive control is the
assisted folding by 70S ribosome (for heparin and BSA experiments) or by 23S rRNA (for tRNA experiment).
doi:10.1371/journal.pone.0002174.g005
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PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2174Figure 6. 6AP and GA specifically bind to some common positions on domain V of large rRNA and inhibit the in vivo protein folding
activity of the ribosome in E. coli.a .Chemical foot printing analysis of binding of 6AP and GA on various RNA. Asterisks indicate positions
protected of degradation by Pb
2+. Note that only 6AP and GA are able to protect some common positions specifically on Domain V of B. subtilis 23S
rRNA (right gel) b. The increase in b-Gal activity was determined as a function of time in E. coli cells induced by IPTG and treated by the indicated
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postulating that in affinity chromatography experiments, the
immobilized drugs retain the entire ribosome.
To our knowledge, 6AP and GA are the first reported
compounds that selectively (i.e. without any significant effect on
protein synthesis) inhibit the protein folding activity of the
ribosome. Indeed, a number of antibiotics like chloramphenicol,
lincomycin and erythromycin, which are known to bind the
central large loop of domain V of 23S rRNA, inhibit the 23S
rRNA/domain V-mediated protein folding activity but also
strongly affect protein synthesis (thereby providing antibacterial
activity) [20]. In contrast, antibiotics like streptomycin or
kasugamycin, which bind to the 30S subunit of the ribosome
and also block protein synthesis, have no effect on the protein
folding activity of the ribosome which is borne by its 50S subunit.
Therefore, as the first molecules specifically inhibiting the protein
folding activity of the ribosome, 6AP and GA confirm that this
activity is independent (or at least uncoupled) from its function in
protein synthesis [25,26]. In addition, these compounds constitute
precious tools to study the yet largely unexplored biological role
and significance of the protein folding activity of the ribosome in
vivo.
At present, it cannot be excluded that, in addition to ribosome-
assisted protein folding, 6AP and GA target other cellular
processes that could account for their antiprion effect. However
we detected no direct interaction between 6AP or GA and prion
proteins. Moreover, all proteins identified in our affinity
chromatography experiments are ribosome-associated. Important-
ly, we observe a strict correlation between the antiprion activity
and inhibitory effect on ribosome-assisted folding of our different
molecules. Therefore, although there is no direct evidence of a
causal link between inhibition of ribosome-assisted folding activity
and prion destabilization, the simplest interpretation of our results
is that the domain V of the large rRNA is the functional target of
both 6AP and GA. We thus propose that ribosome-assisted protein
folding might be involved in prion propagation both in yeast and
mammals. Since ribosome structure and function are largely
conserved throughout evolution, this hypothesis would account the
universality of the antiprion effect of 6AP and GA. Of note is the
fact that RNA molecules strongly increase PrP transconformation
in vitro [44,45]. Indeed, total hamster brain RNA fractionation
experiments showed that RNA molecules of more than 300
nucleotides (that co-purify with rRNA) retain this amplification
ability whereas smaller RNA do not. In addition, the putative
function of the largest rRNA in prion formation/propagation
provides mechanistic support for previously unexplained observa-
tions in yeast showing the ability of 3 mm plasmid (encoding
rRNA) to induce [psi
2]t o[ PSI
+] conversion when introduced into
a[ psi
2] strain [46]. Very recently, it has been shown that in
Drosophila melanogaster, overexpression of chaperone-like highly
structured RNA induces congophilic aggregates and facilitates
neurodegeneration [47], also suggesting that a highly structured
RNA alone could be able to trigger neurodegeneration through
chaperone-like facilitation of protein misfolding and aggregation.
If the causal link between down-regulation of protein folding
activity of the ribosome and prion destabilization remains to be
established, as the first molecules that specifically affect protein
folding activity of the ribosome, 6AP and GA already stand out as
prime new tools to decipher the bona fide biological role(s) of this
chaperone-like activity of the ribosome.
Materials and Methods
Yeast strains, yeast-based antiprion assay and genetic
manipulations
Yeast strains used in this study were as follows. 74-D694: Mata,
ade1-14, trp1-289, his3D200, ura3-52, leu2-3,112,[ PSI
+] [27], Strg6:
Mata, erg6::TRP1, ade1-14, trp1-289, his3D200, ura3-52, leu2-3,112,
[PSI
+] and SB34: Mata, erg6::TRP1, dal5::ADE2, ade2-1, trp1-1, leu2-
3,112, his3-11,15, ura2::HIS, [URE3] [29] and were grown and
used as described [30].
Yeast-based antiprion screening assay
This assay was done as previously described [29,30]. Briefly,
yeast cells containing either [PSI+] or [URE3] prion lead to the
formation of white colonies on rich (YPD) medium whereas, once
cured of these prions ([psi2] or [ure3-0] cells), they lead to the
formation of red colonies, due to the accumulation of a metabolic
byproduct of the adenine biosynthesis pathway in ade1- or ade2-
cells. In the case of the [PSI+] prion, this accumulation is
decreased in [PSI+] cells due to the increased tendency of
ribosome to read through stop codon of the ade1-14 mutant allele
of the ADE1 gene, caused by sequestration of most of Sup35p (a
termination factor homolog of eRF3 in mammals) in prion
aggregates. In the case of the [URE3] prion, the accumulation of
the metabolic byproduct is decreased in [URE3], ade2- cells due to
the expression of a WT copy of the ADE2 gene under the control
of the DAL5 gene promoter which is normally repressed in [ure3-
0] cells [29,48]. An aliquot (350 ml of an 0.5 OD600 overnight
culture) of [PSI+] or [URE3] cells (which grow as white colonies)
were spread using sterile glass beads on square (12 cm612 cm)
Petri plates containing YPD medium supplemented with 200 mM
Guanidine hydrochloride (-GuHCl- conditions where the sensi-
tivity of the method is optimal). Sterile small filters (similar to the
ones used for antibiograms) were then placed on the agar surface
and individual compounds were applied to each filter. The Petri
plates were then incubated three days at 25uC. When a compound
is active against [PSI+] or [URE3] prions, a halo of red colonies
appear around the filter where it was spotted whereas colonies
remain white in case of inactive compounds. To confirm that
potentially active compounds really cure yeast prions and do not
act against the colorimetric system used as a reporter, cells from
the red halos were streaked on a fresh drug-free YPD medium to
control that they still form red colonies, an indication that [PSI+]
or [URE3] prions were actually cured in these cells [30,31].
PrP
Sc inhibition assay in MovS6 cells
Scrapie (127S strain)-infected neuroglial cells (MovS6 [35]) were
treated for 6 days at 37uC, 5% CO2 with 0 to 20 mM of the
indicated drugs or, as controls by the corresponding volume of
DMSO. Cells extracts were then digested with proteinase K and
analyzed by Western blotting using antibody Sha31 (mouse,
dilution 1/5000) directed against PrP protein [49]. Quantification
compounds. Whereas both choramphenicol and streptomycin immediately and very efficiently inhibit translation, only chloramphenicol leads to an
immediate inhibitory effect on increase in b-Gal activity, due to the fact that it also inhibits the protein folding activity of domain V of the large rRNA
of the largest subunit of the ribosome. The increase observed in the presence of streptomycin corresponds to the folding by the ribosome of b-Gal
translated just before translation inhibition by the antibiotic. This increase was inhibited by GA but not by GAi.
doi:10.1371/journal.pone.0002174.g006
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Sc compared to controls was done using the
Vilber-Lourmat Photodocumentation Chemistart 5000 imager.
Preparation of 6AP- and GA- resins
The preparation of the conjugates of 6AP and GA, depicted
respectively in Figures 2 and 3 will be published elsewhere (Gug
et al., submitted). The conjugates were coupled in 0.2 M
NaHCO3, 0.2 M NaCl, pH 8.5 on Fast flow CNBr Activated
Sepharose 4BH supplied by Amersham. The final calculated
concentration was 5–25 mmol/ml of resin. The remaining active
group were blocked in pH 8.0 buffer containing 1 M ethanol-
amine.
Preparation of cell extracts and affinity chromatography
on immobilized drugs
The homogenization buffer for yeast cell extracts was 25 mM
Tris (pH 7.4), 100 mM NaCl, 0.2% Triton X100 and 1 mM
PMSF. The homogenization buffer for porcine brain extracts was
60 mM b-glycerophosphate, 15 mM p-nitrophenyl phosphate,
25 mM MOPS (pH 7.2), 15 mM EGTA, 15 mM MgCl2, 1 mM
sodium vanadate, 1 mM NaF, 1 mM dithiothreitol, 1 mM phenyl
phosphate, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml of
soybean trypsin inhibitor and 100 mM benzamidine. The
homogenization buffer for Mov cell extracts was 50 mM Tris
(pH 7.4), 0.5% sodium deoxycholate, 0.5% Triton X100. At the
end of the preparation procedure, yeast RNA extracts were
resuspended in water treated by Di Ethyl Pyro Carbonate (DEPC).
Yeast protein extracts were obtained from a culture growing at
30uC (OD600 nm=0.8). Cell pellets were resuspended in homog-
enization buffer (300 ml/100 ml of culture) and lysed using acid
washed glass beads (purchased from Sigma, 300 ml/100 ml of
culture). Homogenates were vortexed for 30 sec followed by
30 sec ice-cooling (six times) and then centrifuged for 3 min at
3,000 rpm at 4uC. Supernatants were recovered, assayed for
protein content (using Bio-Rad protein assay) and immediately
loaded batchwise on the affinity matrix.
Porcine brain extracts were obtained from a local slaughter-
house (Louis Gad SA) and directly homogenized and processed for
affinity chromatography or stored at 280uC prior to use. Tissues
were weighed, homogenized and sonicated in homogenization
buffer (2 ml/g of material). Homogenates were centrifuged for
10 min at 14,0006 g at 4uC. The supernatants were recovered,
assayed for protein content (using Bio-Rad protein assay) and
immediately loaded batchwise on the affinity matrix.
MovS6 cell extracts were obtained from a culture grown at
37uC, 5% CO2, washed with PBS 16 and homogenized in
homogenization buffer (1 ml for a 25 cm
2 culture flask).
Homogenates were incubated for 10 min at 4uC and centrifuged
for 1 min at 2,000 rpm at 4uC. The supernatants were recovered,
assayed for protein content (Micro BCA, Pierce) and immediately
loaded batchwise on the affinity matrix.
Just before use, 6AP and GA beads were washed with 1 ml of
bead buffer (50 mM Tris (pH 7.4), 5 mM NaF, 250 mM NaCl,
5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40, 10 mg/ml of
leupeptin, aprotinin, and soybean trypsin inhibitor, and 100 mM
benzamidine) and diluted 4 times in this buffer. Protein extracts:
200 mg of yeast protein extract, or 2 mg of porcine brain or
MovS6 cell protein extract were added to 40 ml of diluted beads
(10 ml of packed beads). The volume was adjusted to 600 mlb y
adding bead buffer, the tubes were rotated at 4uC for 30 min.
Competitions with free active or inactive drugs were performed
with free compounds (or the corresponding volume of DMSO) at a
final concentration of 1 mM incubated with cell extracts for 3 min
before the mixture was added to the affinity matrix. Then, bead
buffer containing the same quantity (1 mM) of free drugs was
immediately added (as described previously) to reach a final
volume of 600 ml. After a brief spin at 10,0006 g at 4uC and
removal of the supernatant, the beads were washed 4 times with
bead buffer before addition of 35 mlo f2 6Laemmli sample buffer.
Following heat denaturation for 3 min at 95uC, the bound
proteins were analyzed by SDS-PAGE and Western blotting or
silver staining as described below.
Electrophoresis, Silver staining, Western blots and
antibodies
Following heat denaturation for 3 min at 95uC, the proteins
bound to 6AP or GA matrices were separated by 10% SDS-PAGE
(precast NuPAGE -Invitrogen- 1 mm thick gel) followed by
immunoblotting analysis or silver staining using an Amersham
SDS-PAGE silver staining kit. For immunoblotting, proteins were
transferred to 0.45 mm nitrocellulose filters (Schleicher and
Schuell). These were blocked with 5% skimmed milk in Tris-
buffered saline/Tween 20, incubated for 1 H with the indicated
antibodies, and analyzed by Enhanced Chemiluminescence (ECL,
Amersham) using a Vilber-Lourmat Photodocumentation Che-
mistart 5000 imager.
Antibody anti-PrP used: Sha31 (mouse, dilution 1/5000) [49].
Antibody anti-Sup35p used: rabbit polyclonal raised against
peptide 55–68 of Sup35p, a kind gift of S. L. Lindquist, dilution
1/1000. Antibody anti-Ure2p used: rabbit polyclonal anti-Ure2p,
a kind gift of L. Maillet, dilution 1/5000.
PMCA assays
All tested compounds were resuspended in DMSO to make
12.5 mM stock solutions and stored at 220uC prior to use.
Working solutions were prepared by serially diluting the stock
solution into water.
To make normal mouse brain homogenate, two frozen mouse
brains (Harlan Sprague Dawley, Inc., Indianapolis, IN) were
Potter homogenized in 10 ml of ice-cold PBS (phosphate-buffered
saline without calcium or magnesium) containing Complete
protease inhibitors (Roche, Indianapolis, IN). The homogenate
was centrifuged at 2006 g for 30 sec, and the post-nuclear
supernatant was collected.
Protein Misfolding Cyclic Amplification (PMCA) reactions
consisted of 50 ml 10% normal mouse brain homogenate, 40 ml
RML scrapie brain homogenate (diluted 1/200 into PBS, 1%
Triton X-100, 5 mM EDTA), and 10 ml tested compounds or
control buffer (8% DMSO in water). Intermittent sonication was
performed in 0.5 ml thin-walled PCR tubes using a Misonix
3000MPD device, using a variation of the semi-automated
procedure originally described [50]. The sonicator output setting
was 6.0, and a 30 sec pulse was delivered every 30 min for 24 H.
The sonicator horn was filled with 350 ml water, which was
maintained at 41uC.
Following PMCA reactions, all samples were treated with
25 mg/ml proteinase K for 1 H at 37uC, subjected to SDS-PAGE,
and transferred onto a PVDF membrane which were subsequently
probed with monoclonal antibody 6D11 (Signet, Dedham, MA) at
1/15000 dilution in TBST.
MALDI-TOF Peptide Mapping Protein Identification
The protein bands were excised from a one-dimensional SDS-
PAGE gel stained by Coomassie blue and digested in gel with
trypsin as described previously [51]. MALDI analysis and
interpretation were realized by Innova Proteomics (Rennes,
France).
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The dipeptide formation assay was designed following [43], in a
cell-free bacterial translation system made up of highly purified
components from E. coli [52]. An initiation complex (IC)
containing E. coli 70S ribosome, [
3H]f-Met tRNA
f-Met, an mRNA
coding for fMet-Leu-Ile-stop, and all three bacterial initiation
factors was prepared, with or without the indicated drugs (6AP,
6APi, GA or GAi) at a final concentration of 1 mM. In parallel, a
ternary complex (TC) containing Leucine, tRNA
Leu, Leu-tRNA
synthetase, EF-Tu, EF-Ts and GTP was prepared. The reaction
was initiated by rapid mixing of the IC and TC in a quench-flow
instrument. The reaction was quenched at different time-points by
addition of formic acid, then the amount of [
3H]f-Met-Leu
dipeptide was quantified in HPLC equipped with an on-line radio
detector [53]. In vitro translation assay based on the rabbit
reticulocyte lysate (Ambion kit) was used according to the
instruction of the manufacturer. Translation of the control capped
mRNA (encoding for EF1a from Xenopus laevis) provided in the kit
was evaluated in presence of the various compounds all at a final
concentration of 200 mM. Autoradiography and quantification
were made using a Storm 840 Phosphorimager (Molecular
Dynamics).
A first in vivo translation assay was performed using a yeast
culture grown at 30uC in YPD (OD600 mm=0.6 in exponential
phase of growth) incubated with the indicated molecules (100 mM)
or the corresponding volume of DMSO (compound vehicle) for
10 min at 30uC at which time [
35S] methionine was added for
10 min. Crude yeast extracts were then realized as described
previously and analyzed by SDS-PAGE. The gel was dried and
analyzed using a Storm 840 Phosphorimager (Molecular Dynam-
ics). A second in vivo translation assay was performed as previously
described [54] and analyzed by two dimensional SDS-PAGE.
In vitro ribosome assisted folding assays
E. coli ribosome, S. cerevisiae ribosome and 50S subunit were
prepared using sucrose gradient zonal ultracentrifugation as
described previously [55]. 23S rRNA was isolated from 50S
subunit by 8 successive phenol-chloroform (1:1) extractions. The
aqueous phase containing rRNA was precipitated by addition of 2
volumes ethanol and 0.1 volume of 5 M sodium acetate pH 5.2.
As the 23S rRNA from different bacterial species has identical
secondary structure, especially in the central loop of the domain V,
we have chosen to transcribe in vitro the 660 nt long domain V of
23S rRNA, due to the availability of the respective clone in
plasmid pDK105 [56]. The plasmid was linearised using EcoRI
and the run off RNA was then transcribed from the SP6 promoter
using SP6 RNA polymerase (GE Healthcare). The DNA template
was digested with RNase-free Dnase I and RNA was precipitated
with ethanol after phenol-chloroform extraction. Further the RNA
concentration was evaluated using Nanodrop spectrophotometer.
The bulk tRNA was purified as described [57]. Heparin was
purchased from Lovens Kemiske Fabrik (Denmark) and BSA from
Promega.
For the in vitro refolding experiments, human Carbonic
Anhydrase (hCA) at a concentration of 20 mM was denaturated
using guanidium hydrochloride 6 M and EDTA 30 nM. To allow
refolding, hCA was then diluted 100 times (final concentration
200 nM) in a buffer containing 20 mM Tris HCl (pH 7.5),
100 mM NaCl and 5 mM magnesium acetate for 30 min with or
without the folding modulators (each at 100 nM final concentra-
tion, except for the in vitro transcribed domain V which is at
150 nM) and/or the drugs (all at 1 mM final concentration). The
refolding of hCA, as a function of its activity, was followed by the
colorimetric assay measuring the increase of A400 with time when
the substrate of hCA, para-nitrophenyl acetate (pNPA), was added
at a final concentration of 500 mM directly to the refolding mix.
In vivo ribosome assisted folding assays
E. coli strain (MRE600 [18]) was grown in LB medium to an
OD600 nm of 0.15 at which time b-Gal expression was induced by
adding IPTG to a final concentration of 1 mM. The culture was
then splitted in different flasks in which 6AP, or 6APi (both at
100 mM final concentration), GA or GAi (both at 200 mM final
concentration) were added. After one hour of incubation,
streptomycin (17 mM final concentration), or chloramphenicol
(464 mM final concentration) or the corresponding volume of
DMSO were added to the indicated cultures. At the indicated
times, 1 ml of the various cultures was collected. Bacteria were
lyzed by mixing immediately 500 ml of collected fractions to
500 ml of toluene whereas the remaining 500 ml were used to
determine OD600 nm. Bacteria in toluene were vortexed for 30 sec.
and then left at room temperature before an additional round of
vortexing. The aqueous phases were then collected and the levels
of b-Gal activity were determined as previously described [58].
Miller units were calculated using the formula [(1000*
OD420 nm2(1.75* OD550 nm))]/[time of reaction in min.*volume
of lysate in ml* OD600 nm].
Chemical foot printing analysis of binding of 6AP and GA
to various RNA
The chemical footprinting analysis were performed in the
presence of freshly prepared PB(OAc)2 solution as previously
described [59]. E. coli RNase P RNA and tRNA
Ser, and domain V
of B. subtilis 23S rRNA were transcribed in vitro and labeled with
32P-pCp at the 39 end. The RNAs were subjected to Pb
2+-
hydrolysis (5 mM) for 5 to 7 mins, in the absence or presence of
the antiprion drugs 6AP and GA or their inactive derivatives 6APi
and GAi respectively, at a final concentration of 1 mM in DMSO.
The alkaline hydrolysis and the G-specific RNase T1 digestion
were performed under denaturating conditions, according to the
manufacturer’s protocol (Ambion). The footprint as well as the
control assays (DMSO-treated) were separated on denaturing 8%
polyacrylamide gels and further analysed using a Phosphorimager
(Molecular Dynamics 400S).
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0002174.s001 (0.02 MB
PDF)
Figure S1 Amyloid aggregation of purified fungal prion proteins
in the presence of 6AP and GA and their inactive derivatives. We
have analyzed the amyloid formation rate of purified recombinant
Ure2p yeast prion protein in the presence of 6AP and GA and
their inactive derivatives (Figure S1a). Aggregation kinetics were
followed by light scaterring. Fibril formation was verified at
polymerisation end points by ThT fluoresence (not shown) and
Ure2p fibril morphology was also analyzed by EM. There is
currently no molecule described to inhibit Ure2p amyloidogenesis
that could have been used as a positive control in these
experiments but since Congo red was decribed as an antiprion
drug acting in cis and is known to delay amyloid formation in
some systems [1], we chose to also included it in this experiment.
Neither 6AP nor GA affected prion amyloid formation rate of
Ure2p significantly while CR had a slight inhibitory effect. 6APi
also induced a modest delay in amyloid formation. However, the
compound was not fully soluble in the used conditions. Ure2p
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inactive derivatives (Figure S1c). The same experiment was also
performed with the prion forming domain of HET-s, a fungal
prion protein. There again, neither 6AP nor GA affected
significantly amyloid formation. Once more, the only compound
that exerted a significant effect were CR and 6APi which here
accelerated aggregation significantly (Figure S1b). It has been
described previously that CR can have an inhibitory or pro-
aggregative effect depending on the considered peptide or protein
[1]. Amyloid formation rate of the Ure2p and HET-s PFD were
monitored at pH 7 and 37uC in the presence of antiprion drugs
and inactive derivatives. Prion aggregation was monitored by
measuring the scattering at 600 nm. The kinetics of the
aggregation at 10 mM of protein in absence or in the presence
of 1 mM of GA, GAi, 6AP, 6APi or 0.01 mM of Congo Red (CR)
were determined and the half-aggregation times have been
obtained for (a) Ure2p aggregation, (b) HET-s PFD aggregation.
(c) Ure2p amyloids have been analyzed at reaction end points by
electron microscopy, scale bar is 100 nm. In these experiments, we
found no correlation between the antiprion activity of the GA and
6AP and their inactive derivatives and their effect in cis on prion
amyloid formation using purified recombinant proteins. 1. Frid P,
Anisimov SV, Popovic N (2007) Congo red and protein
aggregation in neurodegenerative diseases. Brain Res Brain Res
Rev 53: 135–160.
Found at: doi:10.1371/journal.pone.0002174.s002 (2.68 MB TIF)
Figure S2 6AP and GA antiprion drugs do not inhibit protein
synthesis. a - Effect of antiprion drugs on in vitro translation. The
formation of f-Met-Leu dipeptide was assayed in an in vitro
translation system based on purified E. coli ribosome in the
presence of 1 mM of 6AP, 6APi, GA and GAi. None of the tested
drugs showed a significant effect on the kinetics of translation. b -
Effect of antiprion drugs on general in vivo translation in living E.
coli cells. E. coli strain (MRE600 [1]) was grown in LB medium to
an OD600 nm of 0.15 at which time b-Gal expression was
induced by IPTG. Bacteria were then incubated in the presence of
100 mM of 6AP or 6APi, 200 mM of GA or GAi, streptomycin
(17 mM) or chloramphenicol (464 mM) as described in the material
and methods section (paragraph ‘‘In vivo ribosome assisted folding
assays’’). Cells were then incubated in the presence of radiolabelled
[35S] methionine for 10 minutes, harvested and lysed in RIPA
buffer. Equivalent quantities of cell lysates were analyzed by SDS-
PAGE followed by autoradiography. 1. Chattopadhyay S, Pal S,
Pal D, Sarkar D, Chandra S, et al. (1999) Protein folding in
Escherichia coli: role of 23S ribosomal RNA. Biochim Biophys
Acta 1429: 293–298.
Found at: doi:10.1371/journal.pone.0002174.s003 (0.86 MB TIF)
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